Validation of the Modified Glasgow Prognostic Score in Advanced Cancer Patients Receiving Palliative Care

Abstract Context The modified Glasgow Prognostic Score (mGPS) is a well-known marker of systemic inflammatory response previously associated with poor prognoses in cancer. Objectives We investigated the relationships between mGPS and clinical variables and the prognostic impact of mGPS in patients w...

Full description

Saved in:
Bibliographic Details
Published in:Journal of pain and symptom management 2016-02, Vol.51 (2), p.270-277
Main Authors: de Paula Pantano, Naitielle, RN, Paiva, Bianca Sakamoto Ribeiro, RN, PhD, Hui, David, MD, MSc, Paiva, Carlos Eduardo, MD, PhD
Format: Article
Language:English
Subjects:
Aged
Anesthesia & Perioperative Care
Cancer
Female
Glasgow Prognostic Score
Humans
inflammation
Male
Middle Aged
Multivariate Analysis
Neoplasms - diagnosis
Neoplasms - therapy
Pain Medicine
palliative care
Palliative Care - methods
Patient Acuity
Prognosis
prognostic markers
Prospective Studies
Regression Analysis
Survival Analysis
Tertiary Care Centers
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Abstract Context The modified Glasgow Prognostic Score (mGPS) is a well-known marker of systemic inflammatory response previously associated with poor prognoses in cancer. Objectives We investigated the relationships between mGPS and clinical variables and the prognostic impact of mGPS in patients with advanced cancer starting palliative care (PC). Methods Data from two prospective studies conducted at a tertiary cancer center were analyzed ( N  = 459). Data regarding patient characteristics, Karnofsky Performance Status, and blood samples were collected at the initial evaluation. The mGPS was calculated as follows: C-reactive protein (CRP)  10 mg/L = 1, CRP > 10 mg/L and albumin < 35 g/L = 2. Chi-square or Fisher exact tests were used for comparisons of categorical variables; continuous variables were compared using the Mann-Whitney U test. For the survival analysis, Cox regression analyses were performed. Results mGPS of 0, 1, and 2 were assigned to 79.7%, 6.8%, and 13.5% of the patients, respectively. A positive association between hepatic metastasis ( P  = 0.004), primary lung cancer ( P  = 0.021), PC only ( P  
ISSN:0885-3924
1873-6513
DOI:10.1016/j.jpainsymman.2015.09.010